Acute myeloid leukaemia therapeutic innovation and clinical trials: past, present and future

Research output: Contribution to journalArticlepeer-review

Colleges, School and Institutes

Abstract

Outcomes in acute myeloid leukaemia have improved steadily over the last six decades thanks to advances in disease classification, risk stratification and the advent of new drug and transplant therapies. Over this period the UK has made a major contribution to this international effort, both through its delivery of large prospective randomised trials with integrated genomic and measurable residual disease assessments and its pioneering role in the development of allogeneic stem cell transplantation as a potent anti-leukaemic therapy.

Details

Original languageEnglish
Pages (from-to)568-572
Number of pages5
JournalBritish Journal of Haematology
Volume191
Issue number4
Early online date15 Nov 2020
Publication statusPublished - Nov 2020

Keywords

  • AML, therapeutic innovation, clinical trials